ROSETTA Lung-220: A Phase 2, Open-Label, Multicenter, Multi-Arm Platform Study Evaluating Pumitamig and Other Novel Neoadjuvant Regimens in Participants With Resectable, Early-Stage (IIA to IIIB) Non-Small Cell Lung Cancer

Inclusion Criteria * Participants must have newly diagnosed, previously untreated participants with histologically confirmed non-small cell lung cancer (NSCLC) (squamous or non-squamous histology); resectable Stage IIA to IIIB (N2) disease (American Joint Committee on Cancer (AJCC) 9th edition). * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * Participants must have an evaluable programmed death-ligand 1 (PD-L1) expression. Exclusion Criteria * Participants must not have unresectable disease, N3 nodal involvement, or any evidence of…